SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-19-023446
Filing Date
2019-09-12
Accepted
2019-09-12 16:54:21
Documents
2
Period of Report
2019-09-12

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 9719
2 EX-24 DOCUMENT attachment1.htm EX-24 5002
  Complete submission text file 0000899243-19-023446.txt   16181
Mailing Address SATSUMA PHARMACEUTICALS, INC. 400 OYSTER POINT BOULEVARD, SUITE 221 SOUTH SAN FRANCISCO CA 94080
Business Address
Kollins John A (Reporting) CIK: 0001391070 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39041 | Film No.: 191090851

Mailing Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080
Business Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080 415-505-0809
Satsuma Pharmaceuticals, Inc. (Issuer) CIK: 0001692830 (see all company filings)

IRS No.: 813039831 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations